Member

AperionDx


AperionDx develops scalable, ultra-sensitive protein diagnostic technologies leveraging standard qPCR instruments. The company's solutions enable rapid, accurate, and cost-effective detection of disease biomarkers from blood samples, supporting clinical research, drug development, and potential clinical diagnostics, with a focus on neurological diseases like traumatic brain injury and Alzheimer's disease. AperionDx emphasizes accessibility and scalability for laboratories and clinics while continually expanding applications for its technology.

Industries

N/A

AperionDx

6076 Corte Del Cedro, Carlsbad, California 92011, USA


Products

Assay panel quantifying Aβ40, Aβ42, pTau181, and pTau217 from blood, enabling early detection of Alzheimer's disease with high sensitivity and specificity using standard qPCR systems.

Assay panel quantifying GFAP, ALDOC, NGRN, BDNF, and ST2 from blood samples for early assessment, risk stratification, and monitoring of traumatic brain injury using qPCR systems.


Services

Develops custom ultra-sensitive protein biomarker assays for research, drug and companion diagnostics, tailored for use on standard qPCR platforms.

Expertise Areas

  • Protein biomarker diagnostics
  • Neurological disease detection
  • High-throughput assay development
  • Analytical sensitivity optimization
  • Show More (2)

Key Technologies

  • Protein quantification by qPCR
  • Multiplex biomarker panels
  • Ultra-sensitive immunodetection
  • Automated high-throughput screening

Key People

Chief Executive Officer

Chief Scientific & Operating Officer

VP, Sales and Marketing


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.